(S702). Risk-Aligned Management Guided by the Tissue Systems Pathology Test Can Improve Health Outcomes in Barrett’s Esophagus and Reduce Healthcare-Associated Costs This study evaluated the ...

Epigenetic test for risk-stratification impacts gastroenterologists' decision making and improves confidence when caring for patients with Barrett's esophagus. Presentation Title: A COMMUNITY-BASED ...

Epigenetic test for risk-stratification impacts ... care of patients diagnosed with precancerous Barrett's esophagus. The prospective study evaluates the clinical utility of real-world Esopredict ...

Presentation Title: A COMMUNITY-BASED STUDY TO ASSESS A PROGNOSTIC ASSAY ... a highly sensitive epigenetic test designed to predict the risk of progression to high-grade dysplasia or esophageal ...

Epigenetic test for risk-stratification impacts ... when caring for patients with Barrett's esophagus. Presentation Title: A COMMUNITY-BASED STUDY TO ASSESS A PROGNOSTIC ASSAY'S IMPACT ON ...

Presentation Title: A COMMUNITY-BASED STUDY TO ASSESS ... highly sensitive epigenetic test designed to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in ...

NEW YORK – Gastrointestinal health firm Previse said Tuesday that it has been awarded a $1.8 million grant from the National Institutes of Health for the development and commercialization of an ...

This particular screening, called the Esoguard, is a DNA test for detection of esophageal precancer. The test assesses genes from cells collected non-invasively from the esophagus, using a test ...

a key component of its EsoGuard Esophageal DNA Test. "This patent strengthens the already robust intellectual property portfolio underlying our groundbreaking technologies and will provide strong ...